Travellers to Spain risk claim rejection over weight-loss jabs if they miss this important insurance step

People travelling to and from Spain could see travel insurance claims refused after using popular weight-loss injections without declaring them properly. A tightening of insurer rules on GLP‑1 medicines such as Ozempic, Wegovy and Mounjaro means anyone on these treatments must record them when buying cover, or face the prospect of large medical bills and rejected claims while abroad.

What are the rules for travelling with the medicines

Weight loss injections have exploded across many parts of the world and are now a hugely popular choice for many people, but insurers now treat GLP‑1 injections as prescription medicines that form part of your medical history. A 2026 review of 48 UK providers found 26 explicitly require disclosure of weight‑loss jabs, while others expect you to declare the underlying condition such as obesity or type 2 diabetes. The Association of British Insurers (ABI) reiterates that any prescribed medication or treatment must be shared at the point of purchase.

Non‑disclosure can breach policy terms. Several major brands, including Aviva, AXA and Admiral, warn that failing to declare the condition for which the jab was prescribed may lead to rejected claims or reduced payouts, even if the incident appears unrelated. Staysure and other specialist underwriters will consider cover, but only if the medication is prescribed by a GP or registered pharmacy, recorded in medical notes, and part of a supervised programme.

What this means for anyone travelling to and from Spain

Those taking out insurance for their travels must ensure their policy reflects current health circumstances. A claim for severe dehydration, pancreatitis, or an accident complicated by side effects could be scrutinised if the jab was not declared. Airport clinics and private hospitals in coastal areas will expect proof of insurance before non‑emergency treatment. Without valid cover, bills can quickly reach thousands of euros, especially if repatriation is required. Declaring the jab upfront avoids that risk and keeps options open for assistance lines and cashless networks.

What you should do now if getting travel insurance

Declare the medication and the condition. Enter Ozempic, Wegovy, Mounjaro or the generic name during medical screening, and list obesity, diabetes or weight management as the reason.

Expect a premium adjustment. Which? found average quotes rose around 15% after disclosure in a recent sample, though prices vary by age, destination and trip length.

Carry proof of prescription. Keep a GP letter or pharmacy receipt, plus original packaging, in hand luggage. This helps at borders and with overseas clinicians.

Check storage rules. Most GLP‑1 pens need refrigeration before first use. Use a cool bag and confirm airline and destination guidance on carrying injectables.

Use reputable sources. Private or off‑label use without medical oversight can invalidate cover. Be honest on the application form.

Real experiences: what travellers are saying

Online discussions among people using tirzepatide (Mounjaro), semaglutide (Ozempic, Wegovy) and other GLP‑1 jabs show confusion around declaration boxes and online forms. Two comments from a travels forum capture the issue clearly for readers. One traveller, who has tried twice with different insurers, says “there is no channel to report tirzepatide during the application. The form asks to tick conditions, they select obesity, then the questionnaire jumps to unrelated questions such as whether they use breathing apparatus for sleep. Height and weight are requested, yet there is no field to add weight‑loss treatment details”. This gap leaves people unsure whether they have done enough to comply.

Another user, travelling with a spouse, lists all required conditions but finds no space to record medication linked to obesity. Both are near a BMI of 30 after weight loss and are willing to declare tirzepatide, yet the process offers no obvious place to do so. Their advice: call the insurer if in any doubt, and check policy wording for keywords such as declaration, exclusion and pre‑existing.

A third voice warns that injections do not invalidate insurance – failing to tell the insurer does. A separate commenter shares a cautionary tale about a woman who did not declare HRT, suffered an unrelated stroke in Spain, and faced a €40,000 hospital bill after the claim was declined. The lesson for GLP‑1 users is the same: declare early, keep records, and do not rely on assumptions.

If your online form has no field for weight‑loss jabs, pick the relevant condition (obesity or diabetes), then phone the underwriter to add the medication to your file and request written confirmation. Keep that email or note with your policy documents. This simple step can prevent a stressful dispute while you are away or back in the UK.

Common questions

Do I need to declare the jab if I feel fine and have no other conditions?
Yes. Insurers view GLP‑1s as prescription medicines. Which? and ABI guidance both state that non‑disclosure can void a policy, even for unrelated claims. Declaring the drug and the reason keeps cover intact.

What if my jab was prescribed privately, not on the NHS?
You still must declare it. Several underwriters will consider cover if the prescription comes from a registered clinician and appears in your medical records, but hiding private use risks claim refusal.

I’m already abroad in Spain. Can I add the jab to my policy now?
Contact your insurer immediately. Some providers allow mid‑term amendments for medical changes, while others may require a new policy. Do not wait until you need treatment, as delays can affect eligibility.

Don’t risk it for the sake of a click in a box or a quick phonecall.